Genetic studies implicating the region of human chromosome 18p11.2 in susceptibility to bipolar disorder and schizophrenia have observed parent-of-origin effects that may be explained by genomic imprinting. We have identified a transcriptional variant of the GNAL gene in this region, employing an alternative first exon that is 5 0 to the originally identified start site. This alternative GNAL transcript encodes a longer functional variant of the stimulatory Gprotein alpha subunit, G olf . The isoforms of G olf display different expression patterns in the CNS and functionally couple to the dopamine D1 receptor when heterologously expressed in Sf9 cells. In addition, there are CpG islands in the vicinity of both first exons that are differentially methylated, a hallmark of genomic imprinting. These results suggest that GNAL, and possibly other genes in the region, is subject to epigenetic regulation and strengthen the case for a susceptibility gene in this region.
Schizophrenia (SZ) and bipolar affective disorder (BPAD, or manic depressive illness) are major psychiatric disorders, each with a worldwide prevalence of B1%. Both are most often characterized by post-adolescent onset, lifelong persistence, and significant genetic risk. While twin studies have clearly demonstrated heritability for these disorders, penetrance is incomplete, suggesting an environmental component in their etiology. The primary manifestations of SZ and BPAD are disturbances of cognition and mood, respectively. However, there are often cognitive impairments associated with BPAD, as well as profound changes in affect associated with SZ. In addition to some epidemiologic similarities, familial aggregation of related disorders suggests that there may be some shared susceptibility factors. This potential nosological overlap is supported by evidence from genetic linkage studies, in which several susceptibility loci have been identified as common to both disorders.
One such chromosomal region was initially identified by Berrettini et al 1 in an affected sib-pair (ASP) analysis of BPAD pedigrees, 18p11.2. This region was subsequently confirmed in several BPAD linkage studies, 2, 3 and provided the maximum LOD score in a study of chromosome 18 in 59 German and Israeli SZ pedigrees. 4 It is worth noting that the study by Schwab et al included 24 cases of affective disorders, including two with BPAD. Interestingly, a parent-oforigin effect was observed in all of these studies. Specifically, there was a significant paternal transmission bias in the BPAD studies. In contrast, Schwab et al found SZ linkage in the 12 families with exclusive maternal transmission. Such parent-oforigin effects are strongly suggestive of imprinting, an epigenetic phenomenon in which a gene is preferentially expressed from one parental allele. Of the known genes in the region of chromosome 18p11.2, GNAL emerged early as an attractive candidate gene for association studies. GNAL encodes the heterotrimeric G-protein stimulatory alpha subunit, G olf . Several reports have identified disturbances in Gprotein activity and/or expression in BPAD, as well as an effect of subchronic dosing of lithium on G olf . 5, 6 In addition, G olf is highly expressed in the nucleus accumbens and dorsal striatum, brain regions that are highly relevant to psychosis and psychostimulant drug action. Interestingly, Schwab et al found a positive association of a microsatellite marker in intron 5 of the GNAL gene with SZ. 4 However, attempts to identify coding region variants of GNAL that associate with BPAD or SZ have failed. Given the preponderance of genetic evidence implicating this locus and the known biology of G olf , we revisited this gene to search for other potentially significant variants.
Here we report the identification of an alternative transcript derived from the GNAL gene, and demonstrate that it encodes a functional G-protein alpha subunit. The more complete genomic structure of GNAL highlights greater similarity to the related gene, GNAS. GNAS is an imprinted gene, suggesting yet another parallel between these two genes that could be highly relevant to the genetic data reported for BPAD and SZ. We then provide experimental evidence demonstrating that GNAL is also subject to epigenetic modification, suggesting that it is an imprinted gene.
Materials and methods
Bioinformatics analysis and isolation of XLG olf A G olf cDNA sequence (L10665) encompassing the full coding region and some of the 5 0 and 3 0 untranslated regions (UTRs) served as the query in a search of human expressed sequence tag (EST) databanks using the WU-Blast2 algorithm. All partial-length, highidentity matches were manually inspected. Hits with novel sequence were compared to the known GNAL gene structure and the draft human genome sequence. A search of mouse EST data suggested a similar splice form. Prediction of CpG islands in regions of the alternative first exons was accomplished with the programs CpGPlot/CpGReport (from the EMBOSS suite of sequence analysis software) using a window of 400 nt, an observed/expected ratio of CG dinucleotides of at least 0.6, and a minimum G þ C content of 0.5. Predicted amino-acid sequences were aligned with the ClustalW program. A first-strand cDNA comprising XLG olf was synthesized from RNA from human striatum obtained from Analytical Biological Services (Wilmington, DE, USA), using the genespecific primer 5 0 -CCTCACAAGAGCTCATACTGC-3 0 and the Superscript first-strand cDNA synthesis kit (Invitrogen, Carlsbad, CA, USA). A full-length cDNA encoding XLG olf was generated by PCR amplification of this cDNA using the primers 5 0 -CACCATGG GTCTGTGCTACAGTCTG-3 0 and 5 0 -TCACAAGAGCT CATACTGCTT-3 0 . The XLG olf cDNA was then directionally cloned into the vector pENTR/D-TOPO (Invitrogen). The cloned PCR product was verified by DNA sequencing. Initial attempts to amplify XLG olf were not successful using the Clontech Advantage 2 PCR kit. A PCR product representing XLG olf was only seen when the conditions were modified to use the Clontech GC melt polymerase and GC melt buffer. The reason for this is probably the high GC content of the alternate exon1 that would need to be resolved in order for the PCR amplification to proceed. Of four XLG olf clones sequenced, two were correct and two had different bases inserted most likely due to the PCR conditions.
Real-time PCR
The RNA samples in which G olf , XLG olf , and b2-microglobulin levels were determined were obtained from commercial suppliers (Ambion, Austin, TX, USA; Stratagene, La Jolla, CA, USA; BD Biosciences Clontech, Palo Alto, CA, USA). All samples had OD 260/280 of 1.8 or greater, as reported by the supplier. Except for the nucleus accumbens (pool of six individuals) and the spinal cord (pool of 49 individuals), all of the RNA samples were derived from one tissue sample. The donors were different for each tissue. Reverse transcription was performed using reagents purchased from Invitrogen. For each RNA sample, cDNA was prepared in triplicate.
Controls for use in absolute quantitation were generated by PCR using plasmids containing G olf or XLG olf and the following oligonucleotides: 5 0 -CAGGATCCTCATCTGTTTGACG (used for G olf and XLG olf ), 5 0 -GGTACCACCATGGGGTGTTTGGGCGGCA CC (used for G olf ), CAAGGAGGCGAGGAAAGTGA (used for XLG olf ). The PCR products were purified using the QIAquick PCR Purification kit (Qiagen, Valencia, CA, USA). The purified control fragments were electrophoresed in ethidium-bromide-containing agarose gels and the concentrations were determined by comparing the intensity of the bands with a curve constructed using the fluorescence of standards with known concentrations.
Taqman one-step PCR mastermix, oligonucleotides, and 5
0 -6FAM/3 0 -MGBNFQ Taqman probes were purchased from Applied Biosystems (Foster City, CA, USA). Taqman assays were performed using the Applied Biosystems PRISM 7700 Sequence Detection System. b2-microglobulin levels were determined using human b2-Microglobulin endogenous control predeveloped assay reagents (Applied Biosystems catalog number 4333766F). For quantitative real-time PCR, the following oligonucleotides were used in detect G olf : 5 0 -AAAGAGCGCCTGGCTTACAAG; 5 0 -GT TTGACGATGGTGCTTTTCC, and the following oligonucleotides were used to detect XLG olf : 5 0 -GACGCAC CGGCTCCT; 5 0 -GATGGTGCTTTTCCCAGACTCA. The sequence of the G olf Taqman probe was 5 0 -ACCAGCC CCCAGGAG and the sequence of the XLG olf Taqman probe was 5 0 -CCAGCCCCGAGCAGC. Each cDNA preparation was run in triplicate Taqman QRT-PCR reactions. G olf and XLG olf levels were calculated by comparing the threshold cycle numbers from Taqman reactions with the cDNA samples to standard curves constructed using known copy numbers of G olf or XLG olf purified PCR products (see above). Relative levels of b2-microglobulin were determined by comparing the threshold cycle numbers from Taqman reactions with the cDNA samples to standard curves constructed using diluted cDNA prepared from total human brain RNA. The levels of Golf or XLG olf were normalized to an endogenous control (b2-microglobulin) in order to normalize for possible variation in RNA loading (ie dividing G olf or XLG olf levels by the b2-microglobulin level normalized the samples).
Generation of recombinant baculoviruses
The XLG olf cDNA described above was introduced into the cloning vector pENTR/D-TOPO between NotI and AscI sites. Recombinant baculovirus encoding human XLG olf was generated with the BaculoDirectedt expression kit (Invitrogen), according to the manufacturer's protocol. The titer of the third-passage viral stock was determined by plaque assay and used as the working stock.
Cell culture and membrane preparation Sf9 cells were suspended in SF 900 II medium containing penicillin (50 U/ml) and streptomycin (50 mg/ml) and cultured at 281C with rotation (125 rpm). Cells were maintained at a density of 2 Â 10 6 to 4 Â 10 6 cells/ml. For infection, Sf9 cells at the density of 2 Â 10 6 cells/ml were infected with baculovirus (E10 8 pfu/ml) encoding human dopamine D1A receptor (obtained from Perkin-Elmer Biosignal, Montreal, Canada), human G olf (PerkinElmer Biosignal), or human XLG olf at the appropriate multiplicity of infection (MOI). After infection for 48 h, cells were harvested for membrane preparation. Cells were harvested by centrifugation at 500 g at 41C. The cell pellets were washed twice with Dulbecco's phosphate-buffered saline (DPBS) at pH 7.4 and suspended in ice-cold 10 mM Tris-HCl with 5 mM EDTA (TE) (pH 7.4) containing a protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN, USA) and sonicated. Following centrifugation at 1000 g, membranes were collected from the supernatant by centrifugation at 20 000 g for 30 min at 41C. The membrane fraction was stored at À801C in TE containing 5% glycerol. CaCl 2 ) at room temperature for 1 h. Nonspecific binding was determined in the presence of 10 mM ( þ )-butaclamol (Sigma-Aldrich) in a total volume of 200 ml. Bound radioligand was collected on GF/C filters using a 96-well cell harvester. Filters were washed five times with 500 ml of cold 50 mM Tris-HCl buffer (pH 7.4) and filter-bound radioactivity determined by liquid scintillation.
SDS-PAGE and immunoblot analysis
Membranes from Sf9 cells expressing the dopamine receptor D1 (DRD1) alone or DRD1 with G olf variants were solubilized in SDS-sample buffer to a final protein concentration of 1 mg/ml and heated at 801C for 5 min. Solubilized proteins were separated using SDS-PAGE and 4-12% gradient polyacrylamide gels. Proteins were transferred to polyvinylidene difluoride (PVDF) membranes and probed with rabbit antiGolf antibody (K-19) (Santa Cruz Reagents, Santa Cruz, CA, USA) diluted at (1 : 5000) and detected with goat anti-rabbit antibody conjugated with horseradish peroxidase (Pierce, Rockford, IL, USA). Immunoreactive bands were visualized by using SuperSignal s West Dura extended-duration substrate (Pierce), according to the manufacturer's instructions. 50 and relative maximum response (E max ) were derived from analysis of the concentration-response curve using nonlinear least-squares regression fit of the GraphPad Prism program. Statistical significance was assessed by analysis of variance (ANOVA), followed by Tukey post hoc test.
Methylation-specific PCR (MSP)
Brain tissue samples were obtained from autopsies performed on patients at the Veteran's Affairs Medical Center (VAMC). Patients or their legal representative gave written consent for autopsy use of brain tissue for research purposes. The Institutional Review Board of the participating VAMC hospital approved consents and protocols. Only brain tissue obtained from autopsies performed within 24 h or less after death was used from individuals with no clinical signs of psychosis. The brain was exposed by a retroarucular incision and removal of the superior calvarium. After removal of the dura, 10-20 mls of CSF was removed from the lateral ventricle before the brain was extracted. CSF pH was measured to determine the agonal state and the remaining CSF aliquots frozen at À701C. The whole fresh brain was removed and placed on crushed ice. The brain was hemisected into two hemispheres, 1/2 brain placed in 10% buffered formalin for neuropathological diagnosis; the other 1/2 brain was separated into cerebral hemisphere, cerebellum, and brainstem, placed on a glass plate covered by aluminum foil and then into a À701C freezer to firm the tissue for cutting, brainstem-15 min, cerebellum-25 min, cerebral hemisphere-40 min. After the appropriate time interval in the freezer, the brain regions were removed from the freezer and sectioned (brainstem cut into 0.5-cm coronal sections, cerebellum cut into 1.0-cm sagittal sections, cerebrum cut into 16 quick, standardized coronal sections). Punch samples were removed with a 5.0 mm ID stainless steel circular punch from the prefrontal cortex, caudate nucleus head, nucleus accumbens, amygdala, hippocampus, anterior thalamus, substantia nigra, and cerebellum, and immediately placed into cold cryovials and stored in a À701C freezer until analysis. DNA was extracted from a portion of each unfixed regional brain punch sample (B100 mg wet weight) using phenol chloroform extraction and ethanol precipitation as per standard protocols. DNA was quantified using spectrophotometry and analyzed for integrity using 0.8% agarose gel electrophoresis and ethidium bromide staining.
Genomic DNA extracted from cell lines, peripheral blood or brain were modified using the CpGenomet Universal DNA Modification Kit (Chemicon International, Temecula, CA, USA). The protocol used was the same as recommended by the manufacturer, with minor modifications. Briefly, 1 mg of genomic DNA in 100 ml of molecular biology grade water was incubated with 200 mM NaOH at 371C for 15 min. After the incubation, 500 ml of DNA modification reagent I, pH 5, was added and the DNA was then incubated at 551C for 20 h. The completion of the chemical modification and DNA cleanup was performed as recommended by the manufacturer. Modified DNA was resuspended in 25 ml of 10 mM Tris/0.1 mM EDTA, pH 7.5, and stored at À201C. MSP was carried out on the modified DNA using primers designed using Chemicon's Primer Design Software or MethPrimer. 7 MSP reactions were carried out using Amplitaq Gold (Applied Biosystems) and the PT-200 DNA Engine (MJ Research, Rneo, NV, USA), using the following conditions: a 9 min initial denaturation step, followed by 35 cycles of amplification using the following conditions: 951C for 45 s, 551C for 45 s, and 721C for 60 s. The PCR reactions were then subjected to electrophoresis in a 1% agarose/TEA gel containing 0.5 mg/ml ethidium bromide. Bands were visualized using GeneGenius Bioimaging System (Syngene, Frederick, MD, USA). The following oligonucleotide primers (MWG Biotech, High Point, NC, USA) were used: 5 0 -GAACAACAAAAACCGATACG TC and 5 0 -GTTCGGTTTAAAGTAGATAAGTCGA to detect XLG olf methylated DNA with an expected product size of 186 bp, 5 0 -TACCAAACAACAAAAAC CAATACAT and 5 0 -GTTTGGTTTAAAGTAGATAAG TTGA to detect XLG olf unmethylated DNA with an expected product size of 190 bp, 5 0 -TAAGAGAGTTA GGCGGTCGC and 5 0 -CCTAATCTAAAATCCCGATAC GAA to detect G olf methylated DNA with an expected size of 218 bp; and 5 0 -GTGTAAGAGAGTTAGGTGGTT GTG and 5 0 -TCCCTAATCTAAAATCCCAATACAA to detect unmethylated G olf DNA with an expected product size of 223 bp. PCR products were cloned and sequenced to verify their identities.
Results

Identification of an alternate transcript encoded by the GNAL locus
The GNAL gene encodes the olfactory type G-protein alpha subunit, G olf . Previous characterization of the human GNAL gene structure identified 12 exons with no splice variants detected. 8 In an attempt to identify novel splice forms of the GNAL gene, the published cDNA sequence was compared to databases of ESTs. All partial-length, high-identity matches were inspected for the presence of DNA sequence that could identify alternate splice forms or novel exons. One such variant corresponded to a new GNAL transcript with an alternative first exon spliced to the known exon 2 of GNAL. This new exon, referred to here as exon 1a, maps to human chromosome 18p11.2, approximately 62 kb telomeric to the published exon 1 (referred to here as exon 1b) of GNAL (Figure 1a) . A transcript containing this alternative first exon and exons 2-12 of GNAL (ie, the entire open reading frame) was subsequently verified by RT-PCR from human striatum.
The identification of an alternative first exon illustrates not only a previously unidentified splice form but also an additional transcriptional start site, and presumably a distinct regulatory promoter region. This gene structure is highly similar to the related gene, GNAS, which encodes the G-protein alpha subunit G as . As the protein encoded by the 5 0 proximal exon 1 of GNAS is longer than the originally identified protein, it was named XLG as (for eXtra Large 9 ). Therefore, the alternative transcript of GNAL will be referred to as 'XLG olf ' .
An open reading frame in exon 1a of GNAL begins with an ATG within a putative Kozak consensus sequence, has an upstream in-frame stop codon, and is conserved between human and mouse. While the predicted amino-acid sequence of XLG olf shares little similarity with the N-terminal region of XLG as , both alternative first exons share a conserved bg subunitbinding domain with the originally described proteins (Figure 1b) . This evidence suggested that the XLG olf transcript may encode a functional G-protein alpha subunit.
CNS expression of G olf and XLG olf PCR analysis of a panel of cDNA libraries from various human CNS regions suggested that the alternate transcripts might have distinct expression patterns (data not shown). Using a Taqman quantitative PCR assay designed to span the exon 1/2 junction of each transcript, we determined the relative distributions of G olf and XLG olf in selected human CNS regions. In agreement with previous studies of the rat and mouse genes, 10,11 the G olf transcript is prominently expressed in the caudate, putamen, and nucleus accumbens. Lower levels of G olf were also detected in the prefrontal cortex, amygdala, hippocampus and hypothalamus, whereas the transcript was barely detected or not detected at all in the spinal cord, substantia nigra, and liver ( Figure 2) . The relative distribution of XLG olf differs markedly from G olf , with the most prominent expression in hypothalamus, prefrontal cortex, and the ventral striatum. In those regions where both transcripts were clearly detected, the absolute levels of XLG olf exceeded G olf only in the hypothalamus, substantia nigra, and spinal cord.
XLG olf encodes a functional G-protein alpha subunit
While it has been demonstrated that G olf couples with the DRD1, 12,13 interaction of DRD1 with the G olf variant XLG olf is uncharacterized. To evaluate coupling of G olf variants to the DRD1, we introduced these constructs into Sf9 cells and determined agonist-induced [
35 S]GTPgs binding, a measure of G-protein activation.
When expressed in Sf9 cells, the apparent molecular weights of G olf and XLG olf were E44 and E51 kDa, consistent with molecular weights predicted from their amino-acid sequences (Figure 3a) . The molecular weight for XLG olf expressed in HEK 293E cells was comparable (data not shown). Figure  3b shows 
Differential methylation of GNAL CpG islands
The genetic linkage of chromosome 18p11.2 to BPAD in multiple studies is associated with a parent-oforigin effect, suggesting genomic imprinting as a mechanism. As the gene structure of GNAL displays extensive similarity to that of GNAS, a complex imprinted locus, 14 we sought to determine whether the GNAL locus is also imprinted. Genomic imprinting involves allele-specific methylation of CpG island regions, defined here as a sequence of at least 400 bp in length with a G þ C content of at least 50% and an observed:expected ratio of CG dinucleotides greater than 0.6. An inspection of the 190 kb GNAL locus reveals that there are CpG islands in the region of both exon 1a and exon 1b (Figure 1a) .
We employed MSP 15 to assess the methylation status of both CpG island regions in the GNAL locus. While there have been no reports of methylation of GNAL in normal tissue, Costello et al reported aberrant and complete methylation of the G olf CpG island in glioma cells. 16 The methylation-sensitive NotI restriction site in this region was used to guide the MSP studies, and the T98G glioma cell line served as a positive control for methylated DNA. As expected, only methylated DNA was detected in the T98G cell line by MSP (Figure 4) . However, both methylated and unmethylated DNA were detected in genomic DNA from human frontal cortex, substantia nigra (Figure 4) , and peripheral blood lymphocytes (not shown), suggesting that GNAL is imprinted. Subsequent cloning and DNA sequence analysis of the methylated PCR product showed that all CpG residues within this genomic region amplified were methylated. Differential methylation of the XLG olf CpG island was detected in the T98G cells, frontal cortex, hippocampus, substantia nigra (Figure 4) , and peripheral blood (not shown). Although failure to The data represent the average of three cDNA preparations from each RNA sample, with each cDNA subjected to Taqman PCR in triplicate; the error bars represent the standard deviation. While in most regions of coexpression G olf is more abundant, XLG olf is the predominant transcript detected in hypothalamus, substantia nigra, and spinal cord. detect the methylated or unmethylated state by this method is not definitive, detection of methylation is convincing evidence of epigenetic regulation of a locus. The G olf and XLG olf CpG islands may be methylated in a tissue-specific manner, a phenomenon observed for some other imprinted genes, most notably GNAS.
Discussion
We have identified a longer functional variant of G olf that we have called XLG olf . This variant is derived from a large region of the GNAL gene that was previously uncharacterized, and is the product of a different transcriptional start site and first exon. Splice variants at the 5 0 and 3 0 UTRs of the rat GNAL gene were identified, but the alternative first exon reported here was not among those findings. 10 However, the availability of the mouse and rat genomes and EST data indicates that the gene structure of GNAL is conserved in rodent. The discovery of exon 1a of GNAL further extends its degree of similarity to the GNAS gene. In addition, we have provided evidence suggesting that GNAL, like GNAS, is subject to genomic imprinting. To our knowledge, this is the first demonstration of an imprinted locus on human chromosome 18p.
Additional matches to ESTs suggest that there may be at least one other exon 3 0 to exon 1a (not shown); however, we were only able to isolate the full-length cDNA reported here. Despite the very similar gene structures of GNAL and GNAS, the nucleotide sequences of the 5 0 ends of the genes do not share a great degree of identity. One clear difference is that there does not seem to be a transcript analogous to the chromogranin-like NESP55 17, 18 in the GNAL locus. Since the functional activity of G olf has been previously demonstrated by heterologous coexpression with DRD1 in Sf9 cells, 19 may reflect a higher ratio of Gprotein to DRD1. However, Western blot analysis showed that G olf expression was greater than XLG olf expression in the cells used for this study. Nevertheless, increases in agonist efficacy may be due to more efficient coupling of G-protein isoforms to receptor. Alternatively, these G olf variants may exhibit differences in GDP-GTP exchange rates.
Both the G olf and XLG olf transcripts are expressed in regions that are relevant to mood and psychosis, such as the nucleus accumbens and prefrontal cortex. In addition, G olf couples to G-protein-coupled receptors (GPCRs), namely the D1 and A2a receptors, that mediate dopaminergic transmission and psychostimulant drug actions in those regions. [22] [23] [24] Apparent functional differences between the isoforms would suggest that changes in the relative expression levels of G olf and XLG olf might alter the pharmacology of the GPCRs that couple to them. The quantitative assay we have established will enable the measurement of absolute expression levels of G olf and XLG olf in cells or tissues under different conditions, such as normal and disease states.
Given the multiple independent observations of parent-of-origin effects in linkage studies of SZ and BPAD with chromosome 18p11.2, the evidence for imprinting at this locus is compelling. It may seem perplexing that studies of different diseases yielding both maternal and paternal parent-of-origin effects could originate from the same locus. However, the example of GNAS once again serves to illustrate how such a range of phenotypes and a single imprinted gene can explain opposing transmission biases. GNAS encodes distinct transcripts that are either biallelically expressed, maternally imprinted, or paternally imprinted in a tissue-specific manner (for review, see Weinstein et al
25
)
. We have not determined the specific allele that is imprinted for each of the GNAL transcripts, as this requires identification of a polymorphism in the transcribed region, access to DNA and RNA from an individual, and unambiguous parental genotypes. However, re-sequencing of GNAL CpG island regions is likely to provide some polymorphic markers that would allow for such a determination.
DNA methylation that constitutes the 'imprint' most often results in repression of transcription. While it is difficult to provide evidence of allelespecific expression in human tissue for the reasons stated above, Costello et al 16 did correlate hypermethylation of the G olf CpG island region with reduced expression in glioma cells. This suggests that methylation of one parental allele would result in silencing, or partial silencing, of GNAL transcription.
Imprinted genes are often found in clusters in the genome, with an imprinting control region mediating allele-specific expression of multiple genes. 26 GNAL is located in a gene-rich region containing both interesting biological candidates for susceptibility and genes that have been positively associated with psychosis. MPPE1, a brain-specific metallophosphoesterase, is transcribed in the opposite orientation as GNAL, and the two genes have overlapping 3 0 UTRs. 27 IMPA2, located within 100 kb of GNAL, is an inositol phosphatase that has been reported to be associated with both SZ 28 and more recently BPAD. 29 It is possible that these or other genes in the region of GNAL may also be subject to epigenetic regulation. GNAL itself has been investigated as a candidate gene for both BPAD and SZ for several years. To date, no coding region variants of G olf have been reported. A strong association with SZ was reported for a microsatellite in the fifth intron, 4 whereas other genetic studies of BPAD and unipolar depression using intronic GNAL polymorphisms have yielded negative results. [30] [31] [32] The results presented here identify a new region of the GNAL gene that has escaped investigation in previous studies. Nevertheless, many validated SNPs have been identified in this region and are available in public databases (see RefSeq NM_182978). Further genetic analysis is warranted.
